Oral tegafur in the treatment of metastatic breast cancer: a phase II study.
Between February 1985 and October 1989, 26 patients previously treated for metastatic breast cancer received oral tegafur, at a median daily dose of 1200 mg. Of these, 21 were evaluable for response. The overall response rate was 29%; six (two in lungs, two in skin and two in lymph nodes) of 44 evaluable lesions (14%) responded to therapy. Haematological toxicity was mild, and no other dose-limiting toxicity was seen. The data indicate some activity in heavily pretreated metastatic breast cancer even after previous 5-FU therapy.
Kajanti
M J
MJ
Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Pyrhönen
S O
SO
Maiche
A G
AG
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D012878:Skin Neoplasms / Q000556:secondary; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*
D005641:Tegafur